Drug Database · Clinicians

Lercanidipine

Brands (4) Zanidip, Hypecare 10, Hypecare 20…Show all

Calcium channel blocker (dihydropyridine derivatives); Antihypertensive PH FDA category

Contraindicated if GFR <30 or dialysisRx · Prescription drug6 PH productsVAT-exempt Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • Severe kidney impairment (GFR <30 mL/min), including dialysis
  • Severe hepatic impairment
  • Strong CYP3A4 inhibitors, cyclosporine, grapefruit
  • Left ventricular outflow obstruction; untreated heart failure; unstable angina or myocardial infarction within 1 month
  • Pregnancy, breastfeeding, women of childbearing potential without contraception
  • Hypersensitivity
renalcarematters.com, reviewed

Dosing: Adult

  • Mild to moderate essential hypertension: 10 mg once daily at least 15 minutes before a meal; titrate gradually to 20 mg if needed (full effect may take about 2 weeks); maximum 20 mg/day
renalcarematters.com, reviewed

Dosing: Altered kidney function

Lercanidipine is a dihydropyridine calcium-channel blocker cleared by CYP3A4 metabolism; levels are about 70% higher in severe kidney impairment and dialysis. Unlike amlodipine, the European label contraindicates it at glomerular filtration rate (GFR) below 30 mL/min, including dialysis, and asks for caution when increasing to 20 mg in mild to moderate impairment. In peritoneal dialysis it can cloud the effluent. It has no US FDA label.

Kidney function measure: European summary of product characteristics (SmPC) uses glomerular filtration rate (GFR, mL/min) for the contraindication; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Usual: 10 mg once daily at least 15 minutes before a meal, preferably in the morning; may increase to 20 mg after about 2 weeks (SmPC).
CrCl 30–59 mL/min
Mild to moderate impairment: start with special care; 10 mg may be tolerated, but increase to 20 mg cautiously (SmPC).
CrCl 15–29 mL/min
Contraindicated: severe kidney impairment (GFR <30 mL/min), including dialysis (SmPC).
CrCl <15 mL/min (not on dialysis)
Contraindicated: severe kidney impairment (GFR <30 mL/min), including dialysis (SmPC).
Hemodialysis (intermittent)
Contraindicated in dialysis (SmPC). Use another calcium-channel blocker (e.g., amlodipine).
Peritoneal dialysis
Contraindicated in dialysis (SmPC). Can cause cloudy peritoneal effluent that mimics peritonitis.
CRRT
Contraindicated in severe kidney impairment (SmPC).
  • Dialyzable? No: dialysis is unlikely to help in overdose (over 98% protein-bound) (SmPC).
  • Monitoring Blood pressure; peripheral edema; heart rate. Avoid grapefruit, alcohol, strong CYP3A4 inhibitors and cyclosporine (contraindicated) (SmPC).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: HPRA (Ireland) product information (October 2022). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not established under 18 years (SmPC).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 10 mg, 20 mg
  • Tablet: 10 mg, 20 mg

Registered products in the Philippines

6 products registered with the Food and Drug Administration (FDA) Philippines list Lercanidipine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products6
Philippine FDA-registered products for Lercanidipine
Package insert
Hypecare 10Lercanidipine Hydrochloride
10mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.
DRP-18990
Oct 14, 2031
Hypecare 20Lercanidipine Hydrochloride
20mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.
DRP-18991
Oct 14, 2031
Lerlet 20Lercanidipine hydrochloride (as hemihydrate)
20 mg Film-Coated TabletWhite Opaque PVC/Aclar -Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit V)India
Camber Pharmaceuticals, Inc.
DRP-15689
Aug 29, 2029
ZanidipLercanidipine
10 mg TabletBlister Pack x 15's (Box of 30's)
RxVAT-exempt
Recordati Industria Chimica E Farmaceutica S.p.A.Italy
Zuellig Pharma CorporationImporter: Abbott Laboratories
DR-XY25482
Dec 15, 2029
ZanidipLercanidipine
20 mg TabletOpaque PVC/Aluminum blister pack x 14's (Box of 28's)
RxVAT-exempt
Recordati Industria Chimica e Farmaceutica S.p.A.Italy
Zuellig Pharma Corp.Importer: Abbott Laboratories
DR-XY30908
Jul 15, 2031
(no brand name)Lercanidipine Hydrochloride
10 mg Film-Coated TabletWhite Opaque PVC/Aclar-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit V)India
Camber Pharmaceuticals, Inc.
DRP-16829
Jul 15, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin)AvoidLercanidipine AUC up about 15-fold (ketoconazole).Contraindicated.
CyclosporineAvoidBoth levels rise (lercanidipine about 3-fold).Contraindicated.
Grapefruit or grapefruit juiceAvoidHigher exposure.Contraindicated.
CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital)Adjust or monitorLess effect.Monitor blood pressure.
SimvastatinMinorSimvastatin AUC up 56%.Give lercanidipine in the morning and simvastatin in the evening.
DigoxinAdjust or monitorDigoxin peak up about 33%.Monitor for digoxin toxicity.
MetoprololMinorLercanidipine bioavailability down about 50%.Dose adjustment may be needed.
AlcoholMinorMore blood-pressure lowering.Avoid.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Peripheral edema
  • Headache, flushing
  • Tachycardia, palpitations

Serious

  • Angina or myocardial infarction (rare, isolated)
  • Hypotension, syncope
  • Angioedema
renalcarematters.com, reviewed

Monitoring parameters

  • Blood pressure; peripheral edema; heart rate. Avoid grapefruit, alcohol, strong CYP3A4 inhibitors and cyclosporine (contraindicated) (SmPC). Kidney
  • Blood pressure
  • Edema
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 10% (fed; high first pass); a high-fat meal increases it about 4-fold
Time to peak1.5 to 3 hours
Half-life8 to 10 hours (effect lasts 24 hours)
Half-life in kidney failure (ESKD) kidneyLevels about 70% higher in severe impairment or dialysis
Protein bindingOver 98% (lower in severe kidney or liver disease)
Metabolism (CYP, transporters)Extensive CYP3A4
Active metabolitesNone (no parent drug in urine or feces)
Renal excretion kidneyAbout 50% of dose in urine as metabolites
Dialyzability kidneyNo (unlikely to help in overdose)
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Health Products Regulatory Authority (Ireland). Lecalpin 10 mg film-coated tablets SmPC (PA2315/186/001) [HPRA (Ireland) product information, October 2022; no US FDA label]. https://assets.hpra.ie/products/Human/27113/Licence_PA2315-186-001_03072025140350.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Accord Healthcare Ireland Ltd.. (2022). Lecalpin 10 mg film-coated tablets (lercanidipine hydrochloride) [Summary of product characteristics, licence PA2315/186/001; text revised October 2022]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/27113/Licence_PA2315-186-001_03072025140350.pdf

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .